Generating a Reproducible Model of Mid-Gestational Maternal Immune Activation using Poly(I:C) to Study Susceptibility and Resilience in Offspring
August 17th, 2022
Maternal infection is a risk factor for neurodevelopmental disorders. Mouse models of maternal immune activation (MIA) may elucidate infection's impact on brain development and function. Here, general guidelines and a procedure are provided to produce reliably resilient and susceptible offspring exposed to MIA.
Maternal infection, including SARS
View the full transcript and gain access to thousands of scientific videos
Overview
This study explores the effects of maternal infection on neurodevelopmental outcomes using mouse models of maternal immune activation (MIA). The research aims to provide guidelines for producing both resilient and susceptible offspring, shedding light on the mechanisms linking maternal health and brain development.
Key Study Components
Area of Science
- Neuroscience
- Developmental Biology
- Immunology
Background
- Maternal infection is a significant risk factor for neurodevelopmental disorders.
- Understanding the influence of maternal immune activation on brain function is crucial.
- Mouse models can elucidate the impacts of maternal health on offspring brain development.
- Insights gained could potentially inform strategies for mitigating risks associated with maternal infections.
Purpose of Study
- To delineate the impacts of maternal infection on neurodevelopment.
- To produce mouse models that yield reliable outcomes regarding offspring resilience or susceptibility to MIA.
- To better understand the biological mechanisms involved in these effects.
Methods Used
- Utilization of mouse models to study maternal immune activation effects.
- Focus on producing resilient and susceptible offspring through specific procedural guidelines.
- Examination of immune responses and neurodevelopmental outcomes in the offspring.
- Detailed protocols for consistent experimental outcomes.
Main Results
- The study establishes parameters for generating offspring showing varied resilience to maternal infection.
- Identification of key factors contributing to neurodevelopmental variations in offspring.
- Potential insights into interventions that could mitigate the risks associated with maternal infections.
Conclusions
- This research highlights the importance of maternal health in offspring brain development.
- The findings provide foundational guidelines for future studies examining maternal infection effects.
- Implications extend to understanding neurodevelopmental disorders linked to maternal immune challenges.
Frequently Asked Questions
Executive Industry Relevance
Reproducible maternal immune activation (MIA) models are critical for de-risking neurodevelopmental disorder targets and clarifying mechanisms of susceptibility and resilience in offspring. This approach enables biopharma teams to interrogate causal pathways and stratify phenotypic outcomes, supporting predictive confidence in early discovery and translational research. Portfolio decisions benefit from robust models that distinguish between resilient and susceptible phenotypes, aligning preclinical findings with human disease relevance.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables mechanistic interrogation of maternal immune pathways impacting neurodevelopment.
- Supports functional target validation by modeling both susceptibility and resilience in offspring.
- Facilitates predictive confidence in linking maternal immune triggers to offspring phenotypes.
- Improves portfolio triage by clarifying biological risk factors for neuropsychiatric disorders.
Screening & Assay Development
- Provides a validated in vivo system for downstream behavioral and molecular assays.
- Standardizes induction of acute inflammatory responses for reproducible phenotypic screening.
- Enables quantitative assessment of behavioral and molecular endpoints in offspring.
- Supports reliable evaluation of candidate interventions targeting MIA-related pathways.
Translational & Preclinical Research
- Aligns preclinical models with human neurodevelopmental disorder domains affected by maternal immune activation.
- Enables risk-adjusted advancement of therapeutic hypotheses based on stratified offspring outcomes.
- Supports biomarker discovery by correlating baseline immunoreactivity with phenotypic susceptibility.
- Facilitates continuity from mechanistic discovery to preclinical validation of interventions.
Pipeline & Workflow Integration
This MIA model integrates into the discovery-to-preclinical continuum by enabling hypothesis testing, phenotypic stratification, and quantitative readouts relevant to neurodevelopmental risk.
- Discovery Biology: Supports hypothesis-driven testing of maternal immune triggers and offspring outcomes.
- Screening: Provides reproducible, quantitative behavioral and molecular endpoints for assay development.
- Analytics: Enables statistical comparison of susceptible versus resilient offspring based on defined criteria.
- Translational Research: Bridges mechanistic findings to disease-relevant phenotypes observed in human NDDs.
- Enterprise Reuse: Offers a standardized, scalable model for repeated use across neurodevelopmental disorder programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in neurodevelopmental risk modeling.
- Operational Value: Enhances reproducibility and standardization of in vivo immune activation protocols.
- Strategic Value: Informs go/no-go decisions by clarifying risk factors and phenotypic outcomes.
- Portfolio Impact: Supports risk-adjusted prioritization of targets and therapeutic strategies for neuropsychiatric disorders.
Implementation Considerations
- Requires expertise in immunology, neurodevelopment, and behavioral phenotyping.
- Demands access to animal facilities and validated poly(I:C) administration protocols.
- Necessitates cross-team standardization of baseline immunoreactivity assessments.
- Adaptation may be needed for different mouse strains or gestational time points.
- Limitations include variability in immune response and phenotypic expression among offspring.
Biopharma FAQs
Chapters in this video
0:04
Introduction
0:48
Baseline Immunoreactivity (BIR) Testing
1:56
Tail Bleed Method for Blood Collection
3:23
Weight Based Method for Mating and Gestational Embryonic Day 12.5 Injection
5:34
Investigation of Alterations in Behavior in Adult MIA and Control Offspring (Optional)
6:35
Results: Investigating Susceptibility and Resilience of Offspring to Maternal Immune Activation
8:15
Conclusion
